Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens
PLOS ONE · 19.03.2025 · 20 (3) · e0318940
DOI: 10.1371/journal.pone.0318940 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 19.03.2025. Verfasst von Christopher Alba und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: HIV Infections, Infectious Disease Transmission, Vertical, Anti-HIV Agents, Broadly Neutralizing Antibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NICHD NIH HHS, NIAID NIH HHS, USAID.
Abstract (Originalsprache)
Background
Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to infants in three distinct settings.
Methods
We simulated infants in Côte d’Ivoire, South Africa, and Zimbabwe using the Cost-Effectiveness of Preventing AIDS Complications-Pediatric (CEPAC-P) model. We modeled strategies offering a three-bNAb combination in addition to WHO-recommended standard-of-care oral prophylaxis to infants: a) with known, WHO-defined high-risk HIV exposure at birth ( HR-HIVE ); b) with known HIV exposure at birth ( HIVE ); or c) with or without known HIV exposure ( ALL ). Modeled infants received 1-dose , 2-doses , or Extended (every 3 months through 18 months) bNAb dosing. Base case model inputs included 70% bNAb efficacy (sensitivity analysis range: 10–100%), 3-month efficacy duration/dosing interval (1–6 months), and $20/dose cost ($5–$100/dose). Outcomes included pediatric HIV infections, life expectancy, lifetime HIV-related costs, and incremental cost-effectiveness ratios (ICERs, in US$/year-of-life-saved [YLS], assuming a ≤ 50% GDP per capita cost-effectiveness threshold).
Findings
The base case model projects that bNAb strategies targeting HIVE and ALL infants would prevent 7–26% and 10–42% additional pediatric HIV infections, respectively, compared to standard-of-care alone, ranging by dosing approach. HIVE-Extended would be cost-effective (cost-saving compared to standard-of-care) in Côte d’Ivoire and Zimbabwe; ALL-Extended would be cost-effective in South Africa (ICER: $882/YLS). BNAb strategies targeting HR-HIVE infants would result in greater lifetime costs and smaller life expectancy gains than HIVE-Extended . Throughout most bNAb efficacies and costs evaluated in sensitivity analyses, targeting HIVE infants would be cost-effective in Côte d’Ivoire and Zimbabwe, and targeting ALL infants would be cost-effective in South Africa.
Interpretation
Adding long-acting bNAbs to current standard-of-care prophylaxis would be cost-effective, assuming plausible efficacies and costs. The cost-effective target population would vary by setting, largely driven by maternal antenatal HIV prevalence and postpartum incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
- IAVI, New York, New York, United States of America.
- Office of HIV/AIDS, Bureau for Global Health, Agency for International Development (USAID), Washington, DC, United States of America.
- Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- Department of Pediatrics, University of California Irvine, Irvine, California, United States of America.
- Department of Pediatrics, Children's Hospital of Orange County, Orange, California, United States of America.
ORCID-Profile: Christopher Alba, Shelly Malhotra, Katerina Chapman, Valériane Leroy, Carlyn Mann, Elizabeth J McFarland, Caitlin M Dugdale
Förderung
- NICHD NIH HHS
- NIAID NIH HHS
- USAID
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- MGH Research Scholars Award
- International Maternal Pediatric Adolescent AIDS Clinical Trials Network
- NIAID
Zitieren
APA
Alba, C., Malhotra, S., Horsfall, S., Barnhart, M. E., Bekker, A., Chapman, K., Cunningham, C. K., Fast, P. E., Fouda, G. G., Freedberg, K. A., Goga, A., Ghazaryan, L. R., Leroy, V., Mann, C., McCluskey, M. M., McFarland, E. J., Muturi-Kioi, V., Permar, S. R., Shapiro, R., …, & Dugdale, C. M. (2025). Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLOS ONE, 20(3), e0318940. https://doi.org/10.1371/journal.pone.0318940
Vancouver
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, et al. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLOS ONE. 2025;20(3):e0318940. doi:10.1371/journal.pone.0318940
BibTeX
@article{Alba2025,
author = {Alba, Christopher and Malhotra, Shelly and Horsfall, Stephanie and Barnhart, Matthew E and Bekker, Adrie and Chapman, Katerina and Cunningham, Coleen K and Fast, Patricia E and Fouda, Genevieve G and Freedberg, Kenneth A and Goga, Ameena and Ghazaryan, Lusine R and Leroy, Valériane and Mann, Carlyn and McCluskey, Margaret M and McFarland, Elizabeth J and Muturi-Kioi, Vincent and Permar, Sallie R and Shapiro, Roger and Sok, Devin and Stranix-Chibanda, Lynda and Weinstein, Milton C and Ciaranello, Andrea L and Dugdale, Caitlin M},
title = {Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {3},
pages = {e0318940},
doi = {10.1371/journal.pone.0318940}
}
EUVIMED